Core Viewpoint - The company, Huaxia Eye Hospital, has announced the lifting of restrictions on shares issued prior to its initial public offering (IPO), allowing for increased liquidity in the market [1][2]. Group 1: Share Structure and Restrictions - After the IPO, the total share capital of the company is 56 million shares, with 503,663,671 shares subject to trading restrictions, accounting for 89.94% of the total [1]. - As of the announcement date, the total share capital has increased to 84 million shares, with 511,171,125 shares under trading restrictions, representing 60.85% of the total [2]. - The lifting of restrictions involves 238,830,000 shares, which is 28.43% of the total share capital [2]. Group 2: Shareholder Information - The restricted shares are held by two shareholders, with a total of 511,170,000 shares, which is 60.85% of the total share capital [3][4]. - The major shareholders include Huaxia Medical Investment (Xiamen) Co., Ltd. and Su Qingcan, who is the chairman and general manager of the company [4]. Group 3: Financial Performance and IPO Details - The company raised a total of 305.28 million RMB from the IPO, with a net amount of 276.85 million RMB after deducting issuance costs [5]. - The original fundraising target was 77.85 million RMB, indicating a significant oversubscription of 198.99 million RMB [5]. - The company was listed on the Shenzhen Stock Exchange's ChiNext board on November 7, 2022, with an issue price of 50.88 RMB per share [5].
破发股华厦眼科5.11亿股解禁 2022年上市超募19.9亿